XM does not provide services to residents of the United States of America.
G
G

GSK


News

UK Stocks-Factors to watch on Nov 19

UPDATE 1-UK Stocks-Factors to watch on Nov 19 Adds new items, updates futures Nov 19 (Reuters) - Britain's FTSE 100 .FTSE index is seen opening higher on Tuesday, with futures FFIc1 up 0.45%. * IMPERIAL BRANDS: Cigarette maker Imperial Brands IMB.L reported forecast-beating operating profit and said it expected another strong performance next year, as revenues from smoking alternatives soared 26%.
G
I
I

GSK drug meets main goal in late-stage study to treat relentless itch

GSK drug meets main goal in late-stage study to treat relentless itch Nov 19 (Reuters) - British drugmaker GSK GSK.L said on Tuesday its experimental therapy, linerixibat, met its main goal in a late-stage trial to treat patients with a so-called relentless itch associated with a rare autoimmune liver disease. The drug resulted in an improvement in itch compared to a placebo, GSK said.
G

GSK Meets Primary Endpoint in Late-Stage Trial To Treat Relentless Itch

BRIEF-GSK Meets Primary Endpoint in Late-Stage Trial To Treat Relentless Itch Nov 19 (Reuters) - GSK plc GSK.L : GSK PLC - GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT GSK PLC - GLISTEN TRIAL OF LINERIXIBAT MEETS ENDPOINT GSK PLC - LINERIXIBAT SHOWS POSITIVE PHASE III RESULTS IN PBC ITCH GSK PLC - PRIMARY ENDPOINT MET WITH SIGNIFICANT IMPROVEMENT IN
G

Gsk PLC Reports 9.5% Stake In 23Andme Holding As Of Nov 12 Versus Previous Stake Of 11.2% As Of Feb 7 - SEC Filing

BRIEF-Gsk PLC Reports 9.5% Stake In 23Andme Holding As Of Nov 12 Versus Previous Stake Of 11.2% As Of Feb 7 - SEC Filing Nov 15 (Reuters) - GSK plc GSK.L : GSK PLC REPORTS 9.5% STAKE IN 23ANDME HOLDING AS OF NOV 12 VERSUS PREVIOUS STAKE OF 11.2% AS OF FEB 7 - SEC FILING Source text: [ID:n0001839882-24-039514] Further company coverage: GSK.L
G

Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job

UPDATE 7-Drugmaker stocks slide as Trump taps vaccine skeptic RFK Jr for US health job Vaccine skepticism concerns impact biotech investor sentiment Shares of European drug makers fall, along with U.S. companies Analysts worry about RFK Jr.'s influence on HHS agencies Updates throughout with detail on stock moves By Samuel Indyk and Ludwig Burger Nov 15 (Reuters) - Shares of major U.S.
A
G
M
P
P
R
S
C
K
C

European pharma stocks slip after Trump taps RFK Jr to lead top US health agency

BUZZ-European pharma stocks slip after Trump taps RFK Jr to lead top US health agency ** Share in healthcare companies drop the most in Europe, hurt by the news that Donald Trump has selected Robert F. Kennedy Jr. , who has previously spread misinformation on vaccines, to lead the country's top health agency ** STOXX 600 Healthcare index .SXDP at -2.09% is the biggest faller among the pan-European indices ** At 1113.76 points, the sub-index is at its lowest in 7 months and is heading for its big
A
G
R
S
U

Healthcare leads Europe lower

LIVE MARKETS-Healthcare leads Europe lower STOXX 600 down 0.6% Healthcare lags GSK, Sanofi fall on RFK Jr. nomination Wall St futures lower Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com HEALTHCARE LEADS EUROPE LOWER A fall in healthcare stocks is leading major European stock indexes lower on Friday, with vaccine markers hit particularly hard after Trump nominated RFK Jr.
G
S
A
E
F
S
U
G

GSK, AstraZeneca fall after Robert F. Kennedy Jr appointed as US health agency head

BUZZ-GSK, AstraZeneca fall after Robert F. Kennedy Jr appointed as US health agency head ** Shares in GSK GSK.L down 4% at 1,299p, while AstraZeneca AZN.L down 2.5% at 10,038p ** GSK shares hit lowest level since October 2022 ** Both GSK, AZN among top losers on FTSE 100 .FTSE index, which is down 0.3% ** U.S President-elect Donald Trump selected Robert F.
A
G
P
U

Europe' vaccine makers fall as Trump picks RFK Jr to lead top US health agency

Europe' vaccine makers fall as Trump picks RFK Jr to lead top US health agency LONDON, Nov 15 (Reuters) - Shares in European vaccine-makers fell in early trade on Friday after U.S. President-elect Donald Trump said he had selected Robert F. Kennedy Jr., who has previously spread misinformation on vaccines, to lead the Department of Health and Human Services.
A
G
S

European stock futures head south

LIVE MARKETS-European stock futures head south Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com EUROPEAN STOCK FUTURES HEAD SOUTH European equity markets look set to open the final day of a choppy week in the red, as investors attempt to digest what Trump and his policies might mean for global stocks.
G
S
A
E
F
U
G

Vaccine makers, packaged food cos slide as Trump taps RFK to head health agency

BUZZ-Vaccine makers, packaged food cos slide as Trump taps RFK to head health agency ** Shares of vaccine makers tumbled at the end of Thursday's trading session as U.S. President-elect Donald Trump selected Robert F Kennedy Jr to head the Department of Health and Human Services ** BioNTech BNTX.O , Moderna MRNA.O , Pfizer PFE.N , GSK GSK.N and San
G
P
P
S
K

GSK Says Blenrep Shows Overall Survival Benefit In 7 Phase III Trial

BRIEF-GSK Says Blenrep Shows Overall Survival Benefit In DREAMM-7 Phase III Trial Nov 14 (Reuters) - GSK plc GSK.L : GSK PLC - GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP GSK PLC - GSK ANNOUNCES OVERALL SURVIVAL RESULTS FOR BLENREP GSK PLC - BLENREP SHOWS OVERALL SURVIVAL BENEFIT IN DREAMM-7 PHASE III TRIAL GSK PLC - BLENREP PLUS BORDEX SHOW
G

GSK Says Ojjaara Approved In Canada For Treatment Of Myelofibrosis In Adults with Anemia

BRIEF-GSK Says Ojjaara Approved In Canada For Treatment Of Myelofibrosis In Adults with Anemia Nov 12 (Reuters) - GSK plc GSK.L : GSK - OJJAARA (MOMELOTINIB) APPROVED IN CANADA FOR TREATMENT OF MYELOFIBROSIS IN ADULTS WHO HAVE MODERATE TO SEVERE ANEMIA Source text: ID:nCNWcLN3wa Further company coverage: GSK.L
G

Britain's GSK down after Jefferies downgrades to 'hold'

BUZZ-Britain's GSK down after Jefferies downgrades to 'hold' ** Shares of British drugmaker GSK GSK.L down 1.75% at 1,372.5p ** Jefferies downgrades co to "hold" from "buy" and cuts PT to 1,525p from 2,000p ** Brokerage sees overhang for co's vaccines (Arexvy and Shingrix) and lower growth in 2025 ** Last month, GSK said its vaccine sales would fall this year, after a weaker-than-expected performance for its respiratory syncytial virus (RSV) and shingles vaccines in the third quarter ** GSK CEO
G
N

Carnival, Natwest Group, Unite Group

EUROPE RESEARCH ROUNDUP- Carnival, Natwest Group, Unite Group Nov 12 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Carnival, Natwest Group and Unite Group, on Tuesday. HIGHLIGHTS * Antofagasta ANTO.L : Barclays raises target price to 2000p from 1500p * Carnival Plc CCL.L : Morgan Stanley raises target price to 1550p from 1250p * GSK GSK.L : Jefferies cuts to hold from buy; cuts target price to 1525p from 2000p * Natwest Group Plc
A
A
A
A
B
B
B
B
B
C
C
C
D
D
D
E
G
G
G
H
L
N
P
A
A
A
B
B
B
D
E
L
N
R

Vaccine makers exposed to political pathogen

RPT-BREAKINGVIEWS-Vaccine makers exposed to political pathogen The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Nov 7 (Reuters Breakingviews) - It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild” on public health policy and championed him again in his victory speech .
G

Vaccine makers exposed to political pathogen

RPT-BREAKINGVIEWS-Vaccine makers exposed to political pathogen The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Nov 7 (Reuters Breakingviews) - It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild” on public health policy and championed him again in his victory speech .
G

Auto Trader, IHG, Whitbread

EUROPE RESEARCH ROUNDUP-Auto Trader, IHG, Whitbread Nov 8 (Reuters) - Securities analysts revised their ratings and price targets on several European companies, including Auto Trader, IHG and Whitbread, on Friday. HIGHLIGHTS * Auto Trader AUTOA.L : Berenberg cuts target price to 830p from 880p * Burckhardt Compression Holding AG BCHN.S : Berenberg raises PT to CHF 753 from CHF 734 * IHG IHG.L : Peel Hunt raises target price to 9700p from 7000p * National Grid Plc NG.L : JP Morgan cuts target pri
A
A
A
A
A
B
B
C
E
G
G
H
J
R
W
A
A
N
S

Vaccine makers exposed to political pathogen

BREAKINGVIEWS-Vaccine makers exposed to political pathogen The author is a Reuters Breakingviews columnist. The opinions expressed are his own. By Robert Cyran NEW YORK, Nov 7 (Reuters Breakingviews) - It would be unhealthy to let Robert F. Kennedy Jr. take charge of U.S. physical well-being. President-elect Donald Trump said on the campaign trail that he wants the anti-vaccine activist to “run wild” on public health policy and championed him again in his victory speech .
G

U.S. FDA proposes ending use of popular decongestant present in cold medicines

UPDATE 3-U.S. FDA proposes ending use of popular decongestant present in cold medicines Adds trade association statement in paragraph 9 Nov 7 (Reuters) - The U.S. Food and Drug Administration has proposed to remove oral phenylephrine, widely used in cold and cough syrups, as an active ingredient in over-the-counter drugs for nasal congestion, stating it is not effective, the health regulator said on Thursday.
G



Conditions

Popular Assets

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.